8)and twotelephonecontacts(weeks5,7); duringtaper,four times (weeks 10, 12, 14, 16) and four telephone contacts (weeks 9, 11, 13, 15) ; during follow-up four times (weeks 18, 23, 29, 42) . To be evaluable, patients had to complete week 6.
Selection criteria
The London and Toronto sites used the same selection criteria. Patients had to: (a) have panic disorder with marked phobic avoidance (agoraphobia with panics) at a 
The treatment
After baseline evaluation at week 0, a psychiatrist gave the medication and an experienced behaviour therapist (psy chiatrist, nurse or other) gave the psychological treatment. Patient contact with the therapists was from weeks 0 to 8. During subsequent taper and follow-up, contact was with the assessor (no more than 30 minutes per out-patient visit or 15 minutes per telephone interview).
Medication
Dosing was as in the Phase 2 Cross-National study (CNCPS, 1992) . Alprazolam tablet strengths were 1.0mg
from weeks 0-8, and during taper were 1.0,0.5,0.375 and 0.25 mg; placebo tablets were matched. Tablets began at week 0 with 1 mg a day, rising to a mean of 6mg a day, or more (up to 10mg a day) if needed to abolish panics, along with marked fall in avoidance. Up to three attempts were made to raise medication to 10 tablets a day. Rise in dose ceased when patients became panic-free with much reduced avoidance, or had undue side-effects, in which case dose was reduced stepwise until tolerance occurred, after which it was raised again. From weeks 8 to 16, medication was tapered no faster than one tablet a day per three days, down to 4mg; below that taper was even slower, with the number of tablets held steady down to 0.25 mg, and thereafter reduced by one tablet a week (the patient did not know the dose). Dose at week 8 decided taper duration (mean of 8.4 weeks, s.d. 1.1), after which treatment ceased.
Psychological treatment
At screening, the assessor and patient agreed which situations were feared and avoided regularly and most needed help (the phobic targets). After randomisation the patient was given the tablets to start after the week 0 session, and met the therapist for 45 minutes to discuss the phobic targets and the therapy rationale and plan. Exposure followed the lines of the manual Living with Fear (Marks, 1978). Cognitive therapy was not used. Treatment sessions, at weeks 1, 2, 3, 4, 6 and 8, began and ended with 15 minutes of audiotaped discussions, between which were two hours of live exposure or an hour of relaxation. All patients kept a daily panic/anxiety and activity diary from weeks0 to 18, and for weeks22, 28, and 42.
Exposure. At week 0 exposure patients were asked to read Chapter 12 on self-exposure from Living with Fear. With the therapist they planned an exposure homework programme starting with the four phobic targets. At weeks 1, 2, 3, 4, 6 and 8, in the first 15 minutes the therapist discussed the patient's diaries since the last visit, rated compliance, and agreed a plan for that day's exposure. Starting from the clinic, the patient then completed two hours of exposure to one or more phobic targets, and rated anxiety every 30 minutes.As fear reduced,exposurefrom the clinicfocused on further phobic targets and then other situations.
At weeks 1 and 2, the patient's two-hour exposure to the phobic targets was with the therapist present initially and then withdrawing to a known spot or telephone. Therapist accompanied exposure lasted a mean of 37 minutes per session (AE, 36 minutes; PE, 38 minutes; London, 36 minutes; Toronto, 38 minutes) and a mean total of 216 minutes across sessions. Very few patients were escorted at weeks3,4,6 and 8. In the fmal 15minutesof the session (at the clinic) the patient and therapist agreed and set self exposurehomeworktasks for one to two hours a day and not less than four times a week, each to be recorded in the activity diary. In weeks 5 and 7 patients did not visit hospital but were telephoned to monitor progress.
Relaxation.At week0 the therapistgaverelaxation
patients three half-hour audiotapes of instructions (Wolpe & Lazarus, 1966) to use for relaxation homework for an hour daily while sitting or lying comfortably and listening to one of the three tapes. In sessions at weeks 1, 2, 3, 4, 6 and 8, in the first few minutes the therapist discussed the patient's diaries, agreed a plan for that day's one-hour relaxation session in the clinic, and checked progress for a few minutes before and after it. Self-relaxation homework was set between sessions for at least an hour daily with a new tape in each of the first three weeksand with any of the three tapes from week 4 onwards. Each relaxation task was to be noted in the diary. No exposure instructions were given; patients who asked about exposure were told â€oe¿ do whatever you wishâ€•.
Patient adherence
At each visit the number of remaining tablets was noted. Venousblood (7 ml) wastaken at weeks0, 4,8, 18,23 and 43 , to analyse plasma benzodiazepines and psychotropic drug levels at Dr David Greenblatt's laboratory at Tufts New England Medical Center. Patients had written instructions how to take medication and do psychological treatment, and had to keep a daily record of drug and exposure or relaxation therapy. The therapist rated compliance at weeks 1, 2, 3, 4, 6, 8, 10, 12, 14, 16 and 18. Outcome measures Assessor and self-ratings were made at weeks 0, 2, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 23 and 43 . In order to remain blind, the assessor was not told, and asked patients not to reveal, the treatment condition.
Phobia
Four phobic targets were each rated 0â€"8by both subject and assessorfor avoidance(total 0â€"32) and for fear (total 0-32). This was a scale modified from Gelder & Marks (1966) .
A 15-itemPhobia Questionnaire (PQ) was completed, each item rated 0â€"8for avoidance and 0â€"8for fear. Five items each concerned agoraphobia, blood injury, and social phobia, yielding three factor scores (each 0â€"40) and total phobia (0â€" 120). Global phobia was also rated (0â€"8). This questionnaire was modified from Marks & Mathews (1979) .
Panic
Attack and Anticipatory Anxiety Scale (developed for this study by Sheehan) rated numbers of spontaneous and situational panics (both major -3 or more symptoms from the DSM-IIIcriteria-and minor-fewerthan 3 symptoms), and anticipatory anxiety (0â€"10 intensity score, and Â¾ of time per day) and 07@ of day panic free. The scale was scored from the patient's panic diary, by consensus between rater and subject.A compositepanicindexwascalculatedas the log of frequency x intensity x duration of panics.
Mood
Three scales were used to rate mood: the Hamilton Rating
Scale ofAnxiety (14items, total score 0â€"56) (Hamilton, 1959) , the Hamilton Rating Scale for Depression (17 items, total score 0â€"52) (Hamilton, 1960) (both rated by the assessor) and the self-rated Beck Depression Inventory (21 items, total score 0â€"63) (Beck et a!, 1961) .
Disability
Disability was self-rated for the areas of work, social and leisure, family, and home, yielding three subscales, each scored 0-10. Work, social, and family adjustment was rated on one 0-8-point scaleby the assessor (Marks, 1985 (Marks, ,1986 .
Global improvement
much worse); the effect of the panic disorder on the patient's life was also rated by the assessor, on a five-point scale (1= worse, 5 = marked). The Symptom Checklist (SCL-90; Derogatis eta!, 1973 )was self-rated by the patient (total score of 0-182). Patients also rated Global Improvement (PGI). Toronto), and their two-way and three-way interactions.
Method of analysis

Results
Patients were referred by professionals; in London self referrals were also accepted (51 of 82 trial entrants). About 10Â¾of enquirers met the cijteria and entered the trial. No study entrant had had previous adequate alprazolam or exposure (no alprazolam non-responders were referred, and only two were excluded owing to non-response to previous exposure Table 1 Means, standard errors and numbers of patients (London and Toronto samples combined) A = assessor-rating, S = self-rating. 
Non-panic measures
Panic
The 10panic measureshad a far greatervariancethat most of the other measures. During treatment, unlike other measures, total major panics fell to week 8 in all four groups, with no significant differences between them (Tables 1â€"3, Fig. 1(d) ). During taper and follow-up, total panics rose slightly in AE but were similarly improved across the four groups at week43. On spontaneouspanics,alprazolambecamesigni ficantly worse than placebocases. At week 23, ex-alprazolam patients were worse than ex-placebo cases on two phobia and three panicmeasures.Total panicsfellmarkedlyin the double-placebo group (PR) from early in treatment through to the end of follow-up.
The percentof patientsfreeof major panicsdid not differ significantly among the four groups, at week 8 being 62Â¾ AE, 43Â¾ PE, 47Â¾ AR, 47Â¾ PR; at week 23 the figures were 58Â¾AE, 76Â¾PE, 54Â¾AR, 72Â¾PR; and at week 43 they were 77Â¾AE, 77Â¾PE, 50Â¾AR, 59Â¾PR. The picture was similar on the other eight panic measures â€"¿ change in total panics from baseline, total number of panics, numbers of (major and minor) situational and spontaneous panics, intensity and duration of anticipatory anxiety, and composite panic index (log of frequency x intensity x duration).
Other analyses
Interactions (site x drug x psychological treatment) were few, weak (none reached P<0.01), and involved primary efficacy measures on only seven out of 95 tests; they are therefore not detailed. The absence of any significant drug x psychological treatment interaction is noteworthy.
Alprazolam with exposure was not significantly better than placebo with exposure.
Other analyses checked that outcome was consistent across different methods of analysis. Post-hoc i-test comparisons of the four treatments (controlled for experiment-wise error due to multiple comparisons) found, like the ANCOVAs, that AE and PE were significantly better than AR and PR throughout treatment and follow-up. AE was significantly better than PE on only 1 out of 34 comparisons up to week 8, and subsequently on none. Repeated measures ANOVA (MANOVA) tested differential relapse trends after treatment ended at week 8 with a four-level treatment factor (AE, PE, AR, PR), a two-level time factor (weeks 0-8, 8-23), and treatment by timeinteraction. During weeks 8-23, comparedwith placebo patients, alprazolam patients lost some of their gains (whether with exposure or relaxation), while PE patients kept or slightly increased theirs. AE patients became slightly and significantly worse than PE patients during weeks 8-23 (Fig. 1) on four primary efficacy variables and on six other variables.
Global improvement
Proportion improved on the CGI, the survival method (SPSS-X; Lavory ci a!, 1984) was used to determine how long patients who improved markedly to criterion (â€˜very much improved' or â€˜¿ much improved' on two successive ratings from weeks 2 to 43) remained so before having major relapse (return to a rating of â€˜¿ minimally improved or worse' at two successive ratings or at week 43). standard deviation of PR at week 0) and on raw scores, which gave a similar result. Table 3 shows effect size on change scores of some of the primary efficacy measures. For panic, the effect size was minimal because of the strong double-placebo effect. For most other measures, by week 4 effect size was greatest in AE, next biggest in PE, and smallest in AR. By week 8 effect size in each group had grown, especially in PE, in which it was now about twice that in AR for phobias. From two weeks post-taper (week 18)onwards, the effect size in PE was slightly greater than in AE and far greater than in AR, while AR's effect had mainly vanished.
Self-referral versus other referral
Outcome in London was similar in self-v. professionally referred patients. All Toronto cases had come via doctors.
Discussion
After aiprazolam withdrawal, the alprazolam effect would have achieved more worthwhile gains than eight weeks did, given that gains did not accrue in any study over weeks 6â€"8, even with high doses of alprazolam. Nor was relapse prevented either by slow taper over 8 weeks (time from first to last tablet being 16 weeks), or by having added exposure (present AR and AE groups both lost gains at taper). The high-dose alprazolam effect might continue as long as drug is given but seems redundant. It has only a non-significant additive effect which disappears on discontinuation and interferes with maintenance of gains at week 18 (see also Ba@o@,lu eta!, 1993a). Most patients accept exposure, which yields twice more therapeutic gains by eight weeks, and which is usually The drop in panic in the PR group is unlikely to be due to the relaxation. In previous studies of panic disorder, the placebo groups had no relaxation (Ballenger eta!, 1988; CNCPS, SPI, 1992 ) yet improved in panic too. The placebo response was seen only in panic, not in agoraphobia and disability, which did not improve with relaxation in controlled studies (Marks, 1987) . Relaxation is, therefore, a good psycho logical placebo in agoraphobia/panic, despite some beliefs in its value. Had relaxation been effective, then the superior outcome on phobia and disability that exposure achieved compared with alprazolam The present study's alprazolam outcome was like that of the Phase 1 (Ballenger eta!, 1988; Lesser eta!, 1988) The design set past results in perspective. All three studies found an early drug effect, but it was small, transient, and seen mainly on non-panic measures. In the present and Phase 1 and 2 studies, the mean percentages of placebo patients who were free of major panics at week 8 were respectively 47%, 50Â°lo, and 65%. In the Phase 2 study alprazolam had no effect on panics in patients who had panic but no avoidance; the authors concluded that the effect of alprazolam in panic disorder was via avoidance, not panic (Maier et a!, 1991) .
Of the present study's PE trial entrants, 62% were much/very much improved at their last CGI rating (mostly weeks 23 or 43) with minimal residual symp toms no longer interfering with daily life. That gains endured is important in a chronic disorder where mean duration was 5-9 years in most studies. In the Phase
In Phase 1 and 2 completers, by week 8 drug effect was absent on panic and other measures (Ballenger eta!, 1988; CNCPS, SPI, 1992; Andersch eta!, 1991) , being significant mainly on â€˜¿ end-point imputation'. This used notional week 8 scores imputed from week 4 scores; it assumed that the many placebo drop-outs at week 4 would have improved no further by week 8 had they stayed in. That assumption was moot (Marks et a!, 1989) as in the Phase 1 and 2 studies (a) almost half the placebo cases dropped out by weeks 3â€"4, (b)placebo gains were rising just before drop-out, and (c) the present double-placebo group (PR) improved further on panic from weeks 4â€"8.
The present short-term outcome of alprazolam also fits that in four other panic trials. In one, Â¼â€"3 mg alprazolam a day had an effect at weeks 1 and 2 but not at weeks 4 and 8 (Chouinard et a!, 1982) . In another (Dunner et a!, 1986) , at 6 weeks 4mg a day alprazolam reduced anxiety but not panic, and that was on end-point analyses -completer analyses were not given (see below), and placebo drop out rate was 43%. In a third study (Tesar eta!, 1987) , at 6 weeks 5 mg alprazolam a day had an effect on panic and anxiety only on completer, not end-point analyses (placebo drop-out rate was 60%). In a fourth study (Pecknold et a!, 1988) , at 5 weeks 3.6mg alprazolam a day was no better than placebo at reducing panic, but was superior on phobic fear and avoidance.
Present results agree too with those in two trials with an exposure contrast group (6mg alprazolam a day (Klosko eta!, 1988), 1.5 mg a day (Fyer et a!, 1987) ). In both trials alprazolam had no significant effect at the end of treatment whereas exposure did. At six-month follow-up (EcheburÃ¼a et a!, 1993) aiprazolam had slightly reduced gains from exposure.
Like alprazolam, other benzodiazepines too have limited transient effects in panic/agoraphobia (Meilman & Uhde, 1986) . Among antidepressants, imipramine by week 4 reduced panic/agoraphobia to a similar limited extent as did alprazolam, and relapse occurred after stopping both drugs, neither drug being better than placebo at six-month follow up (Andersch et a!, 1991) . Antidepressants can enhance exposure as long as they are given (Brown & Hague, 1986) and, unlike alprazolam, do not reduce post-treatment gains from exposure (Sheehan et a!, 1990) . They are especially useful when dysphoria is present.
High-dose alprazolam significantly impaired thera peutic gains from exposure once all treatment was stopped, not while the drug was being taken. This could reflect state-dependent learning -what animals learn while on benzodiazepines or barbiturates is retained less well in the drug-free state (Gray, 1987; Bouton et a!, 1990 ). Higher-dose anxiolytics can interfere with GABA-ergic and other mechanisms involved in memory. In addition, patients who attributed improvement to medication at week 8 had more fear and avoidance of phobic situations and relapsed more subsequently (Ba@okluet a!, 1993b).
As in other studies, the present alprazolam patients became fairly sedated and remained so even at week 8 (O'Suffivan et a!, 1993). Next-day amnesia was noted with triazolam, a related drug (Bixler et a!, 1991) . Cerebral ventricular enlargement was found in users of long-term benzodiazepines for anxiety/ panic (Lader et a!, 1984; Schmauss & Krieg, 1987; Keilner & Uhde, 1988 (Ghosh & Marks, 1987) . Responders to exposure for obsessiveâ€"compulsive disorder showed changes on positron emission tomography in relevant brain areas (Baxter et a!, 1992) ; in time, relevant brain changes will probably be shown in responsive panic/agoraphobia patients too.
Problems with exposure therapy are the frightening and hard work patients have to do, but most manage to complete it. Of present patients who began exposure, 82% completed 8 weeks of it without drug and 85% with drug. The completion rate in a routine behaviour therapy clinic is 75% (Marks, 1987) . Though our study used both therapist-accompanied and self-exposure, the effective component turns out to be self-exposure (Ghosh & Marks, 1987; Marks et a!, 1988; McNamee et a!, 1989; Alkubaisy et a!, 1992) , which is easy for clinicians to supervise and learn.
Confidence in the present study's outcome is strengthened by the results across London and Toronto having been the same, whether during treatment, taper or follow-up. Moreover, the Toronto site participated in the Phase 1 trial, having few placebo drop-outs and results similar to those in the two present comparable groups (AR and PR).
The high placebo drop-out rate at weeks 3â€"4 in the Phase 1 study came from other sites. The present sample included fewer panic patients without phobic avoidance than did the Phase 2 study, but was similar to the samples in the Phase 1 and most other studies of panic disorder. Present results apply to the majority of patients with panic disorder. For panic without agoraphobia, too, modified exposure was superior to alprazolam (Klosko et a!,
1988).
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